Is Avanos Medical (AVNS) overvalued or fairly valued?

MarketChacha shows Avanos Medical's valuation in context — a forward P/E of about 20.0, a price-to-book of about 1.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Avanos Medical's revenue?

Avanos Medical reported revenue of $701.2M for FY2025, with net profit of $-72.9M, per official filings.

What is the share price of Avanos Medical (AVNS)?

Avanos Medical last traded at $24.99, as of 7/24/2026 — a delayed quote shown for education, not investment advice.

Avanos Medical

AVNS · NYSE · Healthcare · United States

Snapshot

TickerAVNS

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees2,287

HeadquartersAlpharetta, United States

Websiteavanos.com

Filings tracked19

About Avanos Medical

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Who owns it

Insiders3.3%
Institutions93.1%
Public & other3.6%

359 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.14.61%
T. Rowe Price Investment Management, Inc.11.38%
Brown Advisory Inc.4.76%
Dimensional Fund Advisors LP4.38%
Armistice Capital, LLC4.27%
Vanguard Capital Management LLC4.21%
State Street Corporation4.21%
Vanguard Portfolio Management LLC2.65%

Largest institutional holders — last updated 3/31/2026.

Forensic scorecard

Latest ROE of -9.4% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-9.2% → -10.4%

Margin has held broadly steady over the period — stable profitability.

Return on equity-9.4%

Latest ROE of -9.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $181.0M · EPS 0.33

Est. earnings growth +50.0%

Next fiscal year

Rev $740.0M · EPS 1.25

Est. earnings growth +25.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$701.2M

Net margin

-10.4%

ROE

-9.4%

Revenue CAGR (2y)

+2.1%

EPS (FY2025)

-1.57

Net profit (FY2025)

$-72.9M

Ask MarketChacha about AVNS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$701.2M	$-72.9M	-1.57	-10.4%	-9.4%
FY2024	$687.8M	$-392.1M	-8.53	-57.0%	-47.3%
FY2023	$673.3M	$-61.8M	-1.32	-9.2%	-5.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$182.2M	$5.1M	0.11	2.8%
2025Q3	$177.8M	$-1.4M	-0.03	-0.8%
2025Q2	$175.0M	$-76.8M	-1.66	-43.9%
2025Q1	$167.5M	$6.6M	0.14	3.9%
2024Q3	$170.4M	$4.3M	0.09	2.5%
2024Q2	$171.7M	$1.8M	0.04	1.0%
2024Q1	$166.1M	$-900,000	-0.02	-0.5%
2023Q3	$171.3M	$-3.7M	-0.08	-2.2%
2023Q2	$169.4M	$-68.1M	-1.46	-40.2%
2023Q1	$159.3M	$-500,000	-0.01	-0.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material agreement, Termination of agreement, Completion of acquisition/disposition, Material financial obligation, Delisting notice, Security holder rights, Change in control, Executive/director change, Bylaw/charter change, Reg FD disclosure, Exhibits
SEC7/30/2026material
8-K — Shareholder vote results, Reg FD disclosure, Exhibits
SEC7/22/2026material
8-K — Other events, Exhibits
SEC7/15/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/2/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC4/14/2026material
8-K — Executive/director change, Exhibits
SEC3/12/2026material
8-K — Material agreement, Other events, Exhibits
SEC2/26/2026material
8-K — Results of operations, Exhibits
SEC2/24/2026material
10-K filing
SEC2/24/2026
8-K — Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

8-K/A — Executive/director change, Exhibits
SEC12/5/2025
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q — FORM 10-Q
SEC11/5/2025
8-K — Executive/director change, Exhibits
SEC10/23/2025material
8-K — Reg FD disclosure, Exhibits
SEC9/15/2025material
8-K — Results of operations, Executive/director change, Reg FD disclosure, Exhibits
SEC8/5/2025material
10-Q — FORM 10-Q
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.